Johnathan Khusid
Urology · New York, NYNPI 1124413364
Payments from drug & device makers
What this record shows
This record is dominated by grants: $25,000 of the $29,959 with a category attached, or 83.4%. Boston Scientific accounts for 96.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $25,365 and has fallen 99.1% since, to $225 in 2025. Among urology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $468.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$29K
- Calyxo, Inc.$153
- Coloplast$125
- Ambu Inc.$121
- Novo Nordisk Health Care AG$114
- EDAP Technomed Inc$100
- plus $374 from 10 others
What the payments were for
- Grants$25,00083%
- Travel & lodging$1,6065%
- Food & beverage$3,32111%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 43 | $28,972 |
| Calyxo, Inc. | 1 | $153 |
| Coloplast | 1 | $125 |
| Ambu Inc. | 1 | $121 |
| Novo Nordisk Health Care AG | 1 | $114 |
| EDAP Technomed Inc | 1 | $100 |
| AbbVie | 3 | $85 |
| Alnylam Pharmaceuticals Inc. | 2 | $58 |
| Progenics Pharmaceuticals, Inc. | 2 | $51 |
| Merck | 2 | $37 |
| Urogen Pharma, Inc. | 1 | $34 |
| Travere Therapeutics, Inc. | 2 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Tolmar, Inc. | 1 | $18 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
| Immunitybio, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$25,700
- LITHOCLAST$245
- Lumenis Pulse 120H$182
- CVAC Aspiration System$153
- GENERAL - THERAPIES$150
- TITAN$125
How this compares
$29,959 in reported general payments places this provider in the 90th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 88 | $5,955 |
| Tamsulosin Hcl | 134 | $1,125 |
| Chlorthalidone | 41 | $365 |
| Effer-KPotassium Bicarbonate/Cit Ac | 17 | $323 |
| Finasteride | 41 | $253 |
| Oxybutynin Chloride ErOxybutynin Chloride | 33 | $237 |
| Potassium Chloride | 15 | $186 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $153 |
| Doxazosin Mesylate | 12 | $118 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $97 |
| Levofloxacin | 12 | $57 |
Paid to pharmacies, not to this prescriber.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Ketan BadaniNew York$285K
- Michael GrassoNew York$284K
- Mantu GuptaNew York$229K
- Robin SmithNew York$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.